Expression of CD40 and growth-inhibitory activity of CD40 agonist in ovarian carcinoma cells (Q34190753)

31 July 2017

title

Expression of CD40 and growth-inhibitory activity of CD40 agonist in ovarian carcinoma cells (English)

1 reference

31 July 2017

1 reference

Yan Zhou

1

1 reference

31 July 2017

Jing He

2

1 reference

31 July 2017

Lan-tu Gou

3

1 reference

31 July 2017

Bo Mu

4

1 reference

31 July 2017

Wei-chan Liao

5

1 reference

31 July 2017

Cong Ma

6

1 reference

31 July 2017

Ping Tang

7

1 reference

31 July 2017

Shi-jie Zhou

8

1 reference

31 July 2017

Yong-jun Zhou

9

1 reference

31 July 2017

Jin-liang Yang

10

1 reference

31 July 2017

publication date

11 March 2012

1 reference

Cancer Immunology, Immunotherapy

31 July 2017

published in

1 reference

31 July 2017

volume

61

1 reference

31 July 2017

issue

10

1 reference

31 July 2017

page(s)

1735-1743

1 reference

Surgical stress promotes tumor growth in ovarian carcinoma.

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1194-0

The prediction of progression-free and overall survival in women with an advanced stage of epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1194-0

Triggering CD40 on endothelial cells contributes to tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1194-0

Upregulation of CD40 expression on endothelial cells infected with human cytomegalovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1194-0

Transmembrane activator and calcium modulator and cyclophilin ligand interactor enhances CD40-driven plasma cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1194-0

Upregulation of antigen-processing machinery components at mRNA level in acute lymphoblastic leukemia cells after CD40 stimulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1194-0

TLR7 and CD40 cooperate in IL-6 production via enhanced JNK and AP-1 activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1194-0

The serine protease plasmin triggers expression of MCP-1 and CD40 in human primary monocytes via activation of p38 MAPK and janus kinase (JAK)/STAT signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1194-0

CD40 in human oral epithelia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1194-0

Constitutive expression of functional CD40 on mouse renal cancer cells: induction of Fas and Fas-mediated killing by CD40L.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1194-0

Expression of CD40 and Fas ligand in Bowen's disease, squamous cell carcinoma and basal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1194-0

Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1194-0

Transfection of CD40 in a human oral squamous cell carcinoma keratinocyte line upregulates immune potency and costimulatory molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1194-0

Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1194-0

The TNF superfamily members LIGHT and CD154 (CD40 ligand) costimulate induction of dendritic cell maturation and elicit specific CTL activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1194-0

Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1194-0

Expression of CD40 and growth-inhibitory activity of CD40 ligand in colon cancer ex vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1194-0

Molecular mechanism and function of CD40/CD40L engagement in the immune system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1194-0

Expression of CD40 and growth-inhibitory activity of CD40 ligand in ovarian cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1194-0

Tumor necrosis factor receptor-associated factor (TRAF) 1 regulates CD40-induced TRAF2-mediated NF-kappaB activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1194-0

TRAF proteins in CD40 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1194-0

Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1194-0

Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1194-0

Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1194-0

A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1194-0

10.1007/S00262-011-1194-0

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

1030151883

0 references

1 reference